LL-37 is unusual among the peptides in this story: it is made by the human body. It is the only member of the cathelicidin family of antimicrobial peptides in humans, a 37-amino-acid chain (its name comes from the two leucines at its start) released from a precursor protein called hCAP18.1
White blood cells and skin cells produce it as part of the innate immune system's first line of defense.1
A synthetic version can be manufactured for research. Being a natural human peptide does not make the manufactured version approved or proven for any use - LL-37 is not an FDA-approved drug.
In plain English: LL-37 is a germ-fighting peptide your own body already makes to protect you.
What the research shows - and what it doesn't
LL-37 is one of the best-studied antimicrobial peptides. Laboratory work shows it can disrupt the membranes of many bacteria (including some drug-resistant strains) and has antiviral and immune-signaling roles, and animal studies have explored it in wound infection and healing.12
These properties are why it is of scientific interest.
What the record does not include is large, well-controlled human trials establishing that giving LL-37 is safe and effective for any condition. As a manufactured therapeutic it remains investigational.12
Why LL-37 excites the antibiotic-resistance world
LL-37 is, in effect, your body's own antibiotic - a peptide your immune cells already make to punch through bacteria (including drug-resistant strains) while also nudging wounds to heal.12
In an era worried about antibiotic resistance, a natural, broad-spectrum defender is a compelling idea, and the laboratory data behind it is deep. Turning that into a proven human therapy
is the work
that remains.
How to read peptide research. Animal-study and cell-study findings describe what happened in a controlled experiment. They are a starting point for investigation, not evidence that a compound works - or is safe - in humans. Peppies does not claim any peptide treats, cures, or prevents any condition.
In plain English: In the lab it kills many germs and helps wounds heal. Turning it into a proven medicine for people is still being worked on.
Is LL-37 legal in 2026?
Here is the direct answer as of July 2026:
It is not an FDA-approved drug. There is no approved LL-37 product for any medical use.
It cannot be lawfully sold as a dietary supplement. The FDA treats unapproved injectable peptides marketed for human use as outside the lawful supplement framework.3
It has no cleared compounding pathway. LL-37 was in "Category 2" of the FDA's interim 503A bulk-substances list (substances raising significant safety concerns). The FDA removed it - with eleven other peptides - from Category 2 in April 2026, but removal did not place it on the approved list.45
It is not (yet) on the July 2026 agenda. Only seven of the twelve were scheduled for the July 23-24, 2026 advisory meeting; LL-37 is among the five expected to be taken up in a later review.46
In plain terms, LL-37 sits in a regulatory gap - out of the explicitly-restricted bucket, but not in any approved one, and still awaiting its own review.
This section is educational and is not legal advice. Rules can vary and change; consult a qualified professional for your situation.
In plain English: The lab-made version isn't approved and has no legal made-to-order path yet.
The regulatory timeline
Sep 2023
FDA places this and other peptides in Category 2 of the interim 503A bulks list, citing safety concerns.4
Apr 2026
FDA removes 12 peptides - including this one - from Category 2. Seven are referred to a July 2026 advisory meeting; the remaining five, including this one, are set aside for a later review.45
Later review (reported as early 2027)
The Pharmacy Compounding Advisory Committee is expected to take up the remaining peptides - including this one - at a subsequent meeting. As of July 2026, FDA had not yet posted an official meeting notice or evaluated-use chart for that session.64
After that meeting
Any committee vote is advisory only. The FDA then decides whether to begin formal rulemaking to add (or not add) the peptide to the 503A list - the stage where public comment carries legal weight.3
The "early 2027" timing is reported by legal and industry analysts of the April 2026 action; treat it as anticipated rather than an officially scheduled FDA date until a Federal Register notice confirms it.64
Where the public comes in
Because this peptide is not on the July 2026 agenda, its public docket has not opened yet. When the FDA schedules its review - and, more importantly, if it later opens formal rulemaking - there will be a public comment window. That rulemaking window is the one that carries legal weight, and it is the moment Peppies is tracking.
Want to know the moment you can comment?
Join the list and we'll send a clear, step-by-step heads-up when a comment window opens - for this peptide and the rest. See also our how-to-comment guide.
LL-37 is not an FDA-approved drug and has no cleared compounding pathway. It was removed from Category 2 in April 2026 but is not on the July 2026 agenda; a later review is expected.46
Isn't LL-37 made by the body?
Yes - LL-37 is a natural human antimicrobial peptide. That doesn't make a manufactured, injected version approved or proven; it remains investigational.1
When will the FDA review LL-37?
It wasn't on the July 2026 agenda. Analysts of the April 2026 action expect the remaining peptides to be reviewed at a later meeting (reported as early 2027); no official FDA notice had confirmed a date as of July 2026.64
Where to learn more
Want to dig into the primary science yourself? These are neutral, authoritative starting points - no sales pitch, just the record:
We link only to independent, authoritative sources - U.S. and international (NIH, FDA, Europe PMC/EMBL-EBI, and the EU/U.S. trial registries) - never to sellers.
U.S. Food and Drug Administration. "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A" (interim list and categories). fda.gov - 503A bulk drug substanceswww.fda.gov
Hyman, Phelps & McNamara. "FDA's Pep(tide) Rally: What Compounders and Industry Need to Know." FDA Law Blog, April 2026 - 12 peptides removed from Category 2; a subset referred to the July 2026 PCAC and the remainder to a later review. thefdalawblog.comwww.thefdalawblog.com
Federal Register. "Pharmacy Compounding Advisory Committee; Notice of Meeting ... Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List." April 16, 2026. federalregister.govwww.federalregister.gov
Frier Levitt. "FDA to Remove 12 Peptides from the Category 2 'Do Not Compound' List: What It Means for Pharmacies," 2026. frierlevitt.comwww.frierlevitt.com
